Does Insurance Cover GLP-1s? Coverage, Requirements & Your Options

GLP-1 insurance coverage is one of the most searched and most misunderstood topics in prescription drug access today. Medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) have shown meaningful clinical results for weight loss and metabolic health, but whether your insurance plan will cover them is a separate question with a complicated answer.

The short answer: it depends. Coverage is determined by your plan type, the diagnosis your provider submits, documented comorbidities, and a set of criteria that vary by insurer. Private employer plans frequently exclude weight loss medications altogether. Medicare's rules are shifting with new programs launching in 2026. Medicaid coverage is decided state by state. And in all three categories, prior authorization requirements add another layer of complexity.

This guide walks through each insurance category, the exact GLP-1 requirements for insurance coverage, how to navigate prior authorization and appeals, and what your options are when coverage is denied.

Why Is GLP-1 Insurance Coverage So Restricted?

The gap between clinical evidence and insurance coverage is largely a cost problem. GLP-1 medications carry list prices between $900 and $1,100 per month. Tens of millions of adults in the United States meet clinical criteria for these drugs. Insurers and employers look at that math and see a significant budget risk.

Three factors drive the restrictions you are most likely to encounter:

• High list prices: The annual cost per patient is substantial, and broad coverage would raise premiums significantly for employer-sponsored plans.

• Large eligible population: Unlike specialty drugs for rare conditions, GLP-1 medications have an enormous potential patient pool. Insurers worry about the cumulative cost of covering millions of patients simultaneously.

• Adherence and return on investment: Many patients discontinue GLP-1 therapy before reaching sustained outcomes, which leads payers to question the long-term value of coverage.

There is also a broader policy debate running underneath all of this. Proponents of GLP-1 coverage argue that treating obesity now prevents far more expensive conditions later, including heart disease, type 2 diabetes, sleep apnea, and chronic kidney disease. Opponents point to the immediate fiscal reality for employers and insurers absorbing the cost. That debate is why GLP-1 insurance coverage remains unsettled and is actively changing in 2026.

Which GLP-1 Medications Are Covered and for What Condition?

The most important factor in GLP-1 coverage is why a medication is prescribed, not just which drug it is. Ozempic and Mounjaro are FDA-approved for type 2 diabetes. Wegovy and Zepbound are FDA-approved for weight management. That distinction directly determines how insurers categorize and cover them.

Ozempic and Mounjaro sit in the diabetes treatment category and are more consistently covered by insurance plans that cover diabetes medications. Wegovy and Zepbound face a higher bar because they are classified as anti-obesity medications, a category many plans exclude or restrict separately.

Off-label uses, including prescribing a GLP-1 for PCOS, prediabetes, or insulin resistance, are generally not covered. Insurers follow FDA-approved indications closely, and prior authorization forms ask specifically about diagnosis codes. If your provider submits a code outside the approved indication for that drug, the request will typically be denied. Your medically supervised weight-loss program should include a provider who can document your full clinical picture, including any conditions that might qualify under an approved indication.

Does Private Insurance Cover GLP-1 Medications?

GLP-1 insurance coverage through private employer or Marketplace plans is inconsistent. Research from the University of Pennsylvania's Leonard Davis Institute shows that patients are facing growing barriers as insurers tighten prior authorization criteria in response to rising demand and costs. Many employer plans specifically exclude weight loss medications as a benefit category, meaning that no documentation will change that outcome because the drug is not on the formulary for that indication.

Even when a plan does offer coverage for GLP-1 medications, expect:

• Prior authorization (PA): Your provider must submit documentation before the pharmacy can fill the prescription.

• BMI thresholds: Typically a BMI of 30 or above, or 27 with one or more documented comorbidities.

• Reauthorization: Every 6 to 12 months, most plans require documented weight loss progress to continue coverage.

• High out-of-pocket costs: Even with coverage, costs can be significant before your deductible is met.

How Major Insurers Approach GLP-1 Coverage

Blue Cross Blue Shield plans vary significantly by region and employer contract. Some BCBS plans cover Wegovy and Zepbound for weight management with standard prior authorization criteria; others have removed them from formulary entirely. Beginning in late 2025, several BCBS plans began restructuring GLP-1 benefits in response to cost pressures.

Aetna currently covers certain GLP-1 medications for weight management when members meet BMI criteria and prior authorization requirements, but coverage is plan-specific and subject to annual benefit changes.

UnitedHealthcare, through OptumRx, has tightened authorization criteria and requires documentation of prior medication trials and comorbidities before approving weight management GLP-1s.

CVS Caremark, which manages pharmacy benefits for many employer plans, applies its own prior authorization criteria including diagnosis codes, BMI measurements, and in some cases A1C levels or cardiovascular risk documentation.

If you are unsure what your specific plan covers, call the member services number on your insurance card and ask directly whether Wegovy or Zepbound is on your formulary for weight management and what the prior authorization requirements are.

Does Medicare Cover GLP-1 Medications?

Medicare's approach to GLP-1 coverage has historically been restrictive. Under standard Medicare Part D rules, GLP-1 medications are covered when prescribed for type 2 diabetes or, for Wegovy specifically, for reducing cardiovascular risk in patients with established heart disease. Coverage solely for weight loss has not been available under the standard Part D framework.

That is changing in 2026 with two significant developments.

The Medicare GLP-1 Bridge Program (July Through December 2026)

The Centers for Medicare and Medicaid Services (CMS) launched a temporary Bridge program to expand GLP-1 access for eligible Medicare beneficiaries while longer-term coverage policy is finalized.

Key details of the Bridge program:

• Eligible drugs: Wegovy (injectable and oral formulations) and the Zepbound KwikPen.

• Cost to you: A flat $50 monthly copay. CMS covers the remaining balance of the $245 monthly program cost.

• Access: Your physician must submit a specific prior authorization through the Bridge pathway. The prescription does not route through your standard Part D plan.

• Important limitation: Costs paid under the Bridge program do not count toward your True Out-of-Pocket (TrOOP) cap, and the program is strictly for weight loss. If you already have Part D coverage for a GLP-1 for diabetes or cardiovascular disease, you should remain on your existing plan.

If you use the Bridge program in 2026, plan to review your Part D coverage during open enrollment later that year to ensure continuity in 2027.

The BALANCE Model (2027 and Beyond)

Starting in January 2027, Medicare plans to transition GLP-1 weight loss coverage to the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) model, which is designed to integrate these medications into standard Part D coverage more permanently.

A meaningful distinction with BALANCE: beneficiaries will likely be required to participate in a structured weight management program alongside medication. Coverage under this model is not medication-only. Understanding this now matters because the program you enroll in at the end of 2026 will determine your 2027 access.

Does Medicaid Cover GLP-1 Medications?

Medicaid is administered jointly by the federal government and individual states, and federal law permits states to exclude anti-obesity medications from coverage. As of January 2026, 13 states cover GLP-1 medications for weight management under Medicaid:

• Delaware

• Kansas

• Massachusetts

• Michigan

• Minnesota

• Mississippi

• Missouri

• North Carolina

• Rhode Island

• Tennessee

• Utah

• Virginia

• Wisconsin

Four states have eliminated GLP-1 coverage for weight management: California, New Hampshire, Pennsylvania, and South Carolina.

If your state is not on the coverage list, check whether a documented comorbidity changes your situation. Many Medicaid programs will cover a GLP-1 when it is prescribed for an approved secondary condition, including obstructive sleep apnea, cardiovascular disease, or chronic kidney disease, even when they exclude weight loss as a standalone indication. Talk with your prescribing provider about how your full clinical picture can be documented in the prior authorization.

GLP-1 Requirements for Insurance Coverage

Understanding the GLP-1 requirements for insurance coverage before your visit lets you and your provider submit a complete prior authorization the first time, which reduces the likelihood of an initial denial.

Most insurers that cover GLP-1 medications for weight management require the following baseline criteria:

• A BMI of 30 or above (obesity), or

• A BMI of 27 or above with at least one documented weight-related comorbidity

Comorbidities That Can Unlock Coverage

This is where many patients miss an opportunity. If your BMI is in the 27 to 29 range, or if your plan requires documented comorbidities even at a BMI of 30 or above, secondary conditions can shift your application from denied to approved. Conditions that commonly qualify include:

• Type 2 diabetes or prediabetes

• Obstructive sleep apnea

• Established cardiovascular disease or high cardiovascular risk

• Hypertension (high blood pressure)

• Dyslipidemia (elevated cholesterol or triglycerides)

• Metabolic-associated steatohepatitis (MASH), also called fatty liver disease

• Chronic kidney disease

Each of these represents a legitimate medical concern in its own right and a documented pathway to coverage approval. Work with your provider to ensure that all relevant diagnoses are included in the prior authorization submission, not only your primary weight management concern. A clinical picture that includes comorbidities is both more complete and more likely to be approved.

Step Therapy and Documentation Requirements

Many plans require proof that you have already tried lower-cost weight management options before approving a GLP-1. Medications commonly listed as required prior steps include phentermine, orlistat (Xenical or Alli), Qsymia (phentermine/topiramate), and Contrave (naltrexone/bupropion). Your provider will need to document what was tried, for how long, and why it was discontinued, whether due to ineffectiveness, side effects, or a contraindication.

Additional documentation typically required in a prior authorization:

• Confirmed diagnosis codes corresponding to your condition

• Current height, weight, and BMI

• A1C results or other relevant lab values

• Weight history showing the duration and pattern of your struggle with weight

• Documentation of lifestyle program participation or prior structured weight management attempts

• A statement of medical necessity from your prescribing provider

How to Get Insurance to Cover GLP-1 Medications

The prior authorization process is where most GLP-1 coverage decisions are made and where most reversals happen as well. Here is a practical step-by-step approach to getting insurance to cover GLP-1 medications.

Step 1: Verify your formulary before the visit. Call your insurer's member services line or check your online member portal to confirm whether Wegovy or Zepbound is listed for weight management under your plan. If the drug is not on the formulary at all, you are dealing with a benefit exclusion rather than a prior authorization issue, and the path forward is different.

Step 2: Prepare your documentation in advance. Bring a list of all weight management medications and programs you have tried, including dates, dosages, and the reason for stopping. Include recent weight history and any relevant lab results. Providing this upfront reduces processing time and prevents incomplete submissions.

Step 3: Your provider submits prior authorization. The PA form typically includes diagnosis codes, BMI, lab values, documentation of prior treatment, and a statement of medical necessity. Incomplete submissions are the most common reason for an initial denial. A well-prepared provider visit is your first line of defense against a denial.

Step 4: The review period. After submission, the insurer's clinical team reviews the case. This typically takes 1 to 10 business days, longer if additional documentation is requested. You can call your insurer to confirm receipt and check status at any point.

How to Appeal a GLP-1 Denial

A denial is not necessarily final. Many initial denials are automated, based on missing or incomplete information rather than a deliberate coverage decision. Here is how to approach an appeal effectively:

1. Get the denial reason in writing. The letter should specify exactly which criteria were not met.

2. Contact your provider to initiate the appeal. Your provider's office handles the clinical documentation.

3. Submit missing documentation. This may include lab values, weight history, or records of prior medication trials.

4. File within the required deadline. Most plans allow 60 to 180 days from the denial date.

5. Request a peer-to-peer review. This step puts your provider in direct contact with the insurer's medical reviewer and resolves many denials that a written appeal alone would not.

6. Escalate to external review if needed. External reviewers are independent of your insurer, and the insurer is legally required to honor their decision. Standard reviews take 30 to 45 days.

A letter of medical necessity from your provider, written to address measurable health risks and comorbidities rather than weight loss as a cosmetic goal, significantly improves outcomes at every stage of this process.

GLP-1 Without Insurance: Your Real Options

If your plan excludes GLP-1 coverage for weight management, or if you do not carry insurance, you have several options beyond paying the full list price. Accessing GLP-1 medications without insurance requires more planning, but it is not out of reach.

Manufacturer savings cards: Each of the major GLP-1 manufacturers offers savings programs for patients with commercial (employer or Marketplace) insurance. These are not available to Medicare or Medicaid enrollees, but for those with private coverage, they can substantially reduce out-of-pocket costs. Savings programs are available through NovoCare for Wegovy and Ozempic, and through LillyDirect for Zepbound and Mounjaro. Eligibility and savings amounts change periodically, so verify current terms directly on the manufacturer's website.

Patient assistance programs: If you meet income requirements, manufacturer patient assistance programs, including NovoCare and Lilly Cares, can provide medication at little or no cost. Applications typically take a few weeks to process but are worth pursuing for patients without adequate coverage.

Mail-order and direct pharmacy options: LillyDirect and the NovoCare Pharmacy offer direct-to-consumer dispensing that can reduce cost compared to retail. Prices for the same drug can vary meaningfully across pharmacies, so comparing options before filling is worth doing.

Medically supervised compounded semaglutide: For patients who cannot access or afford brand-name GLP-1 medications, compounded semaglutide prescribed through a licensed telehealth provider is another pathway. Compounded versions are not FDA-approved brand-name medications, but when prescribed and monitored by a licensed clinician as part of a structured program, they include the clinical oversight that makes GLP-1 therapy both safe and effective. PeakPerforMAX's medically supervised weight-loss therapy program includes a provider evaluation, prescription when clinically appropriate, and ongoing monitoring, without requiring insurance coverage.

The Bottom Line

GLP-1 insurance coverage depends on your plan type, your clinical diagnosis, your documented comorbidities, and your willingness to navigate prior authorization and appeals. Private employer plans frequently exclude weight management GLP-1s. Medicare is opening new pathways in 2026 through the Bridge program and the BALANCE model. Medicaid coverage remains state-specific.

If you have been denied, an appeal is often worth pursuing, particularly when your provider can document comorbidities and prior treatment attempts in detail. If coverage is not available through your plan, compounded semaglutide through a medically supervised telehealth program provides accessible access with the clinical monitoring that GLP-1 therapy requires.

If you are ready to explore whether medically supervised weight-loss therapy is right for your health history and goals, see how PeakPerforMAX's GLP-1 program works.